LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Articles
Synox Therapeutics Ltd.
Headquarters:
Dublin, Ireland
Website:
https://synoxtherapeutics.com/...
Year Founded:
2020
Status:
Private
BioCentury
|
Oct 31, 2024
Finance
Axonis advancing KCC2 program with $115M series A
BioCentury’s Venture Report also includes fundings for Evommune, Blue Earth and more
Read More
BioCentury
|
Apr 26, 2024
Finance
Venture report: Arch, Foresite $1B AI play Xaira starting with Baker lab’s de novo biologics
Plus rounds for Rubedo, Flindr, Endeavor, SynOx and more
Read More
BioCentury
|
Apr 1, 2022
Management Tracks
Morgan Stanley’s Christine Ha becomes CFO at Ventus
Plus new CEO at Zealand Pharma, updates from Nuvalent, Pathalys and more
Read More
BioCentury
|
Aug 4, 2021
Management Tracks
Qian joins LianBio as general manager of China
Hoffman out as Zymergen CEO, plus updates from Scholar Rock, Ironwood, Keros, Madrigal and more
Read More
BioCentury
|
Jul 28, 2021
Management Tracks
Cassidy joins SpringWorks as CMO
Plus: Centogene, Lava, Umoja and SynOx
Read More
BioCentury
|
Apr 21, 2021
Finance
With upsized opportunity fund closing at €360M, Forbion readies to build on portfolio with three-pronged strategy
Forbion is carving out a strategy that’s differentiated from most biotech opportunity funds
Read More
BioCentury
|
Nov 19, 2020
Finance
VCs back Celleron spinout with €37M to develop former Roche asset for rare joint disorder
A European VC syndicate shared Celleron’s belief that a single-asset start-up was the best place to develop emactuzumab, an asset the U.K. biotech obtained after Roche deprioritized it in 2018.
Read More
Items per page:
10
1 - 7 of 7